medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2008, Number 3

<< Back

Dermatología Cosmética, Médica y Quirúrgica 2008; 6 (3)

Xeroderma pigmentosum and basal cell carcinoma. Case report of a child treated with imiquimod and surgery

García VA, Hernández TMM, Balderrama VC, Guzmán SD, Rodríguez CMA, Dávalos RNO

Language: Spanish
References: 28
Page: 198-203
PDF size: 370.32 Kb.


ABSTRACT

A5 years-old male patient with xeroderma pigmentoso (XP), without neurological clinical involvement, with multiple basal cell carcinomas and a pyogenic granuloma. He was treated with 5% imiquimod cream once a day, 5 times per week during 21 weeks and photoprotection with physical blockers SPF60, with marked improvement in lentigo and actinic keratosis, but the surgical excision of the basal cell carcinomas was necessary. We emphazise the importante of both, the education to obtain proper photoprotection and the severe psicosocial and economical consecuences of this genodermatosis.


REFERENCES

  1. Papadopoulos AJ, Schwatz RA, Sarasin A, Lambert WC, “The xeroderma pigmentosum variant in Greek patient”, Int J Dermatol 2001; 40: 442-445.

  2. Liy WMC, Durán-McKinster C, Orozco CL, Sáez OM, Carrasco DD, Ruiz-Maldonado R, “Xeroderma pigmentoso con retraso psicomotor: síndrome de De Sanctis Cacchione. Reporte de dos casos de origen mexicano”, Dermatol Pediatr Lat 2004; 2 (1): 50-53.

  3. Kraemer KH, Lee MM, Scotto J, “Xeroderma pigmentosum Abnor - malities in 830 published cases”, Arch Dermatol 1987; 123: 241-250.

  4. Kan SG, Metin A, Gozukara E, Inui H, Shahlavi T, Muñiz-Medina V et al., “Two essential splice lariat branchpoint sequences in one intron in a xeroderma pigmentosum dna repair gene: mutations result in reduced XPC M RNA levels that correlate with cancer risk”, Oxford Journals 2004; 13: 343-352.

  5. Kahatri ML, Shafi M, Mashina A, “Xeroderma pigmentosum. A clinical study of 24 Libyan cases”, J Am Acad Dermatol 1992; 26: 75-78.

  6. Ríos BL, Ortiz C, Berona AP, Santa CJ, Navarrete FG, “Xeroderma pigmentoso: revisión del tema y presentación de dos casos”, Rev Centro Dermatológico Pascua 1995; 4: 34-38.

  7. Ruiz Maldonado R, Orozco Covarrubias ML, “Malignant melanoma in children. A review”, Arch Dermatol 1997; 133(7): 833.

  8. Chi H, Kawaschi Y, Otsuka F, “Xeroderma pigmentosum variant: dna plidy analysis of various skin tumors and normal-apperind skin in a patient”, Int J Dermatol 1994; 33(11): 775-778.

  9. Lacour JP, “Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms”, Br Dermatol 2002; 146(suppl 61): 17-19.

  10. Sánchez Pedroño PG, Martínez-Liarte JH, “Xeroderma pigmentoso”, Piel 2005; 6: 229-237.

  11. Jung EG, “Xeroderma pigmentosum”, Int J Dermatol 1986; 25(10): 629-633.

  12. Zamudio PG, Moreno LM, Ysita AM, “Xeroderma pigmentoso con alteraciones neurológicas. Reporte de dos casos”, Dermatología Rev Mex 2000; 44: 277-281.

  13. Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH, “Cockayne syndrome and xeroderma pigmentosum: DNA repair dis - orders with overlaps and paradoxes”, Neurology 2000: 55: 1442-1449.

  14. Hessel A, Siegel RJ, Mitchell DL, Cleaver JE, “Xeroderma Pig men to - sum variant with multisystem involvement”, Archives of Dermatology 1992; 128: 1233-1237.

  15. Kraemer K, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL, “Prevention of skin cancer in xeroderma pigmentosum with the use of oral isoretinoin”, N Engl J Med 1988; 318: 1633-1637.

  16. Lens Marko B, Dawes M, “Interferon Alfa Therapy for Ma lig nant Melanoma: A Systematic Review of Randomized Con trol led Trials”, Journal of Clinical Oncology 2002; 20(7): 1818-1825.

  17. Kraemer KH, DiGiovanna JJ, “Topical enzyme therapy for skin diseases?”, J Am Acad Dermatol 2002; 46: 463-466.

  18. Nelson BR, Fader DJ, Gillard M et al., “The role of dermoabrasion and chemical peels in the treatment of patients with xeroderma pigmentosum”, J Am Acad Dermatol 1995; 32: 623-626.

  19. Köning A, Friederich HC, Hoffmann R, Happle R, “Dermabrasion for the treatment of xeroderma pigmentosum”, Arch Dermatol 1998; 134: 241-242.

  20. Geisse JK, Rich P, Pandya A et al., “Imiquimod 5% cream for the treat - ment of superficial basal cell carcinoma: a double-blind, randomi - zed, Vehicle-controlled study”, J Am Acad Dermatol 2002; 47: 390-398.

  21. Marks R, Gabbier K, Sumac S et al., “Imiquimod 5% cream in The treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial”, J Am Acad Dermatol 2001; 44: 807-813.

  22. Nijsten T, Lapiére K, Lambert J, “A patient with xeroderma pigmentosum treated with imiquimod 5% cream”, J Am Acad Dermatol 2005; 52: 170-171.

  23. Seong WY, Duck-Sun A, “Racial resurfacing in xeroderma pigmentosum with chemical Peeling”, Plastic Recons Surgery 1999; 103: 1464- 1467.

  24. Sönmez ES, Isen CE, Demirkesen C, “Is a facial resurfacing with monobloc full thickness skin graft a remedy in xeroderma pigmentosum”, Plastic Recons Surgery 2002; 110: 1290-1293.

  25. Sapijaszko MJA, “Imiquimod 5% Cream (Aldara®) in the Treatment of Basal Cell Carcinoma”, Skin Therapy Lett 2005; 10: 2-5.

  26. Prieto González EA, Borroto López JM, Valdés García F, Pomares Iturralde Y, “Propuesta de manejo terapéutico en un caso de Xero - derma pigmentosum”, Revista Cubana de Investigaciones Biomédicas 1999; 18(1): 40-42.

  27. Nagore E, Sevil A, Sanmartín O, Boletell-Estrada R, Requena C, Serra Guillén C et al., “Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum”, Br J Dermatol 2003: 149; 858-861.

  28. Gianfranco M, Ciambellotti A, Rebora A, “Occlusive Medication with Imiquimod in Bowen’s Disease”, Acta Dermato-Venereológica 2003; 84(2): 168-169.




2020     |     www.medigraphic.com